# Headache on anticancer drugs: assessment, acalabrutinib headache and when it signals something else

Source: https://onco.cc/protocols/headache-on-anticancer-drugs/  
OnCo record `headache-on-anticancer-drugs` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Headache is a common side effect of some cancer medicines. On acalabrutinib it mostly comes in the first weeks, is mild and eases. On blinatumomab it can be a sign of a reaction that your team needs to know about. A sudden severe headache, or one with weakness, confusion, a fit or trouble speaking, is an emergency. Your own team's advice comes first.

## Summary

No oncology guideline on drug-related headache was found; this page joins a general headache guideline to what the labels and three narrative papers say, and the local protocol comes first. Assessment: NICE CG150 (England, over 12s) lists the features that call for evaluation and consideration of investigation or referral (1.1.1 [2012]), and separately a new-onset headache with compromised immunity, a history of malignancy known to metastasise to the brain, or vomiting without other obvious cause (1.1.2 [2012]). The UKONS triage tool (v3) asks about headache in its pain row and says to consider ICANS or CRS.

Acalabrutinib: headache is in 22% to 40% of patients across the trials in the US label (0.6% to 1.7% at grade 3 or above; two of the five tables print grade 3 or 4) and 36.5% on monotherapy in the EU SmPC (grade 3 or higher 1.2%). Three narrative papers, none graded, describe it as early and mild or grade 1 or 2. Two suggest paracetamol or caffeine, avoiding NSAIDs if possible (O'Brien 2021, written with AstraZeneca-funded support, and the Chinese consensus 2023, which follows it); Lipsky and Lamanna 2020 say paracetamol with or without caffeine is often effective and do not mention NSAIDs. Grade 3 or greater non-haematological toxicity is an interruption in both labels (monotherapy or with obinutuzumab): resume at the same dose the first and second time, 100 mg once daily the third, discontinue at the fourth. Both labels warn of serious and fatal bleeding (the EU SmPC names central nervous system haemorrhage; the US label counts any central nervous system bleeding as major haemorrhage); the US patient information lists a headache that lasts a long time among the signs of bleeding to report right away, and the EU leaflet's list does not name headache.

Blinatumomab: the US label gives headache and tremor as the most common manifestations of neurological toxicity, marks headache in its tables as possibly representing ICANS, and lists it among the manifestations of CRS; the EU SmPC recommends a neurological examination before starting. Grading and treatment of ICANS and CRS are in their own protocols. Trastuzumab emtansine (headache 28% in both US label trials) and talazoparib (33% in EMBRACA in the US label, 19.0% in the EU pooled data) list headache with no rule for managing it; talazoparib's labels withhold for grade 3 or 4 non-haematological reactions. For trastuzumab emtansine the only wording that names headache is in the EU texts: the package leaflet says not to drive, cycle or use tools or machines until a headache stops. Both trastuzumab emtansine labels warn of central nervous system haemorrhage and do not connect it to headache.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: acalabrutinib headache; Calquence headache; BTK inhibitor headache; headache during cancer treatment; headache on blinatumomab; headache on Kadcyla; headache on talazoparib; drug-related headache in cancer

## Connected records

- protocols: [Acute oncology telephone triage: the 24-hour helpline and the UKONS red, amber and green grading](https://onco.cc/protocols/acute-oncology-telephone-triage/), [Atrial fibrillation, bleeding and high blood pressure on BTK inhibitors: assessment, monitoring and management](https://onco.cc/protocols/atrial-fibrillation-and-bleeding-on-btk-inhibitors/), [Bleeding precautions at home when platelets are low](https://onco.cc/protocols/bleeding-precautions-when-platelets-are-low/), [Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids](https://onco.cc/protocols/crs-grading-and-management/), [ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management](https://onco.cc/protocols/icans-grading-and-management/), [Oral anticancer medicines at home: prescribing, teaching, adherence, storage, handling and disposal](https://onco.cc/protocols/oral-anticancer-medicines-at-home/), [Raised intracranial pressure in cancer: recognition, urgent scan, dexamethasone and referral](https://onco.cc/protocols/raised-intracranial-pressure/), [T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery](https://onco.cc/protocols/bispecific-step-up-dosing/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Blinatumomab](https://onco.cc/drugs/blinatumomab/), [Talazoparib](https://onco.cc/drugs/talazoparib/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- terms: [CTCAE toxicity grading (grade 3-4 adverse events)](https://onco.cc/terms/ctcae-grading/), [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [ICANS (neurotoxicity)](https://onco.cc/terms/icans/)

---
JSON: https://onco.cc/api/v1/entities/headache-on-anticancer-drugs.json